Cannabis News

ZYUS Life Sciences Launches Two Softgel Cannabinoid Products for Direct to Patient Sales in Canada – Medical Marijuana Program Connection

SASKATOON, Saskatchewan–()–ZYUS Life Sciences Inc. (“ZYUS”), a Canadian life sciences company at the forefront of scientific research and development in herbal medicine, today announced the launch of two new cannabinoid products, Zylem™ 1:20 Softgel Capsules and Zylem™ 5:5 Softgels, both for direct sale and distribution to registered medical cannabis patients across Canada. The launch of these two new softgel products marks another milestone in ZYUS’ mission to elevate cannabinoids as the standard of care and harness their transformative potential.

ZYUS manufactures its cannabinoid extracts in an industry-leading, pharmaceutical-grade extraction facility, with all products undergoing rigorous testing and over 450 quality checkpoints to ensure standardized formulations that patients and healthcare professionals can rely on.

The two Zylem™ Softgel Capsule products each have their own unique color to provide patients with an easy way to identify and distinguish ZYUS softgel formulations. ZYUS places the utmost importance on ensuring that our products are high quality, consistent, easy to administer, and always available to the patients we serve.

“With the launch of Zylem™ Softgels, we are excited to offer patients an additional method of delivering cannabinoids to help manage their condition and associated symptoms,” said ZYUS CEO Brent Zettl. “Our new Zylem™ capsules offer patients a convenient, simple and accurate method for dosing medical cannabinoids.”

Zylem™ Softgel capsules are available for direct sale and distribution to registered medical cannabis patients across Canada. Prospective patients or healthcare professionals seeking more information about ZYUS or its products can visit or speak to a member of the ZYUS Patient Care Team at 1-833-713-CARE (2273).

About ZYUS Life Sciences Inc.:

ZYUS is a Canadian life sciences company focused on the development and global commercialization of innovative cannabinoid-based therapeutics and product candidates. Through clinical research and intellectual property development, we intend to provide patients worldwide with high-quality oils, capsules, topical creams and other cannabinoid-based therapeutic products and candidates. ZYUS’ vision is to elevate cannabinoids as the standard of care and expand the potential of protein-based formulations in pursuit of a transformational impact on patients’ lives. ZYUS: Advancing the science of wellness. Visit

Forward-looking information:

This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of ZYUS to be materially different from any future results, performance or achievements expressed or implied by the statements. prospective. These forward-looking statements include, but are not limited to, expectations regarding our business plans, research activities, product lines, effectiveness and patient services.

Often, but not always, forward-looking statements can be identified by the use of words such as “expects”, “expects”, “expects”, “anticipates”, “believes”, ” intends to”, “estimates”, “predicts”. , “continuing”, “potential”, “targeted”, “anticipates”, “possible” and similar expressions, or statements that events, conditions or results “will”, “may”, “might” , “would” or “should” occur or be achieved, or the negative form of these or other comparable terms. Forward-looking statements are based on certain assumptions, including assumptions regarding ZYUS’ ability to continue to ensure product availability, consistency and quality through robust sourcing, manufacturing and testing processes, and are subject to various known and unknown risks and uncertainties, many of which are beyond the control of the Company and cannot be predicted or quantified and, therefore, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks include the risk that ZYUS may not be able to continue to ensure product availability, consistency and quality through robust sourcing, manufacturing and testing processes.

Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this press release. Because forward-looking statements and information relate to future events and conditions, they, by their very nature, involve inherent risks and uncertainties.

Readers are cautioned that the above list of factors is not exhaustive. The forward-looking statements contained in this press release are made as of the date of this release and, accordingly, are subject to change after such date. ZYUS undertakes no obligation to update or revise any forward-looking statements or information, whether written or oral, which may be made from time to time by us or on our behalf, except as required by applicable law.

#ZYUS #Life #Sciences #Launches #Softgel #Cannabinoid #Products #Direct #Patient #Sales #Canada #Medical #Marijuana #Program #Connection

Related Posts

Leave a Reply